Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Health Care Plan Exjade PA | OpenPa…
    Ask Trek AI about this page
    RetiredVentura County Health Care PlanPolicy N/A

    EXJADE (Deferasirox) Prior Authorization

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and safe-use requirements for deferasirox in transfusional iron overload and non-transfusion-dependent thalassemia, including eligibility, dosing, monitoring, contraindications, exclusions, and restricted-distribution requirements.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyEXJADE (Deferasirox) Prior Authorization
    Policy CodePolicy N/A
    Change TypeArchivedno material clinical or coverage changes
    Effective DateJan 28, 2014
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionPrescribers must enroll patients in EPASS Complete Care before obtaining deferasirox.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was archived following review without documented content revisions.

    2Covered clinical indications
    EPASSRestricted distribution program
    ≥5 mg Fe/gMinimum LIC criterion
    CrCl <40Renal threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Monthly
    Routine monitoring

    Coverage Criteria

    Initial Coverage Eligibility

    Covered when all of the following are met:

    Qualifying indication

    • ONE of

      • Chronic iron overload due to blood transfusions (transfusional hemosiderosis).
      • Chronic iron overload due to a non-transfusion-dependent thalassemia syndrome.
    Non-transfusion-dependent thalassemia laboratory criteria: For non-transfusion-dependent thalassemia, hepatic iron concentration is at least 5 mg Fe/g liver dry weight and serum ferritin is greater than 300 mcg/L.LIC ≥5 mg Fe/g dry weight; serum ferritin >300 mcg/L

    Treatment Initiation, Continuation, and Response Monitoring

    Treatment initiation and continuation must follow the indication-specific laboratory and response criteria.

    Transfusional iron overload initiation: Evidence of chronic iron overload includes transfusion of at least 100 mL/kg of packed red blood cells and serum ferritin consistently greater than 1,000 mcg/L.≥100 mL/kg packed red blood cells; serum ferritin consistently >1,000 mcg/L
    Non-transfusion-dependent thalassemia monitoring and continuation: Monitor serum ferritin monthly and hepatic iron concentration every 6 months; interrupt therapy when serum ferritin is below 300 mcg/L or hepatic iron concentration is below 3 mg Fe/g dry weight, and resume when hepatic iron concentration is above 5 mg Fe/g dry weight.Serum ferritin monthly; LIC every 6 months

    Dose adjustments depend on hepatic iron concentration and treatment duration.

    Safety and Toxicity Criteria

    Treatment requires ongoing safety monitoring and dose interruption or discontinuation for toxicity.

    Renal and hepatic monitoring: Monitor renal function and liver tests at the specified baseline and follow-up intervals, with dose reduction, interruption, or discontinuation when renal or hepatic toxicity thresholds are met.CrCl <40 mL/min or serum creatinine >2 times age-appropriate ULN requires discontinuation; avoid Child-Pugh class C at initiation

    Creatinine monitoring is more frequent initially for patients at risk of acute renal failure.

    Toxicity management: Interrupt, reduce, or discontinue treatment for clinically significant bone marrow suppression, gastrointestinal ulceration or hemorrhage, severe rash or suspected erythema multiforme, hearing or visual disturbance, or severe or persistent transaminase or bilirubin increases.Platelets <50,000/mm3 are a contraindication

    Suspected erythema multiforme requires permanent discontinuation.

    Do not use Exjade for transfusional iron overload or non-transfusion-dependent thalassemia when creatinine clearance is below 40 mL/minute. Use is also excluded when serum creatinine is greater than 2 times the age-appropriate upper limit of normal.

    Do not initiate Exjade in patients with severe hepatic impairment, defined as Child-Pugh class C.

    Avoid Exjade in patients with Child-Pugh class C hepatic impairment. The policy directs dose reduction for Child-Pugh class B impairment and avoidance of use for class C impairment.

    Clinical Thresholds and Dose Parameters

    Transfusion exposure
    Required exposureAt least 100 mL/kg of packed red blood cells
    ExampleAt least 20 units for a 40 kg individual
    Clinical contextEvidence of chronic iron overload due to blood transfusions
    Ferritin initiation threshold
    Initiation thresholdSerum ferritin consistently greater than 1,000 mcg/L
    Applies toTransfusional iron overload
    Required withAt least 100 mL/kg of packed red blood cells

    Provider Requirements and Safety Actions

    Prior Authorization

    Qualifying Indication

    Authorize deferasirox only for chronic iron overload caused by blood transfusions (transfusional hemosiderosis) or a non-transfusion-dependent thalassemia syndrome, with required indication-specific laboratory evidence.

    • Liver iron concentration (LIC) must be at least 5 mg Fe/g liver dry weight.
    • Serum ferritin must be greater than 300 mcg/L.
    Prior Authorization

    EPASS Complete Care Enrollment Required

    Deferasirox is available only through the restricted EPASS™ Complete Care distribution program. Enrollment is required before the medication can be obtained.

    • For patient enrollment assistance, contact 1-888-90-EPASS (1-888-903-7277).

    Therapy Background

    Deferasirox is an oral iron-chelating agent that selectively binds iron and forms a complex excreted primarily in the feces. This policy addresses chronic iron overload associated with repeated blood transfusions and non-transfusion-dependent thalassemia syndromes. Because serious toxicities can occur, treatment requires ongoing renal, hepatic, hematologic, gastrointestinal, auditory, and visual safety monitoring.

    Definitions

    Hepatic iron concentration
    TermLIC
    DefinitionHepatic iron concentration measured as milligrams of iron per gram of liver dry weight
    Policy thresholdsAt least 5 mg Fe/g dry weight for initiation; below 3 mg Fe/g dry weight for interruption in non-transfusion-dependent thalassemia
    Creatinine clearance
    TermCrCl
    DefinitionCreatinine clearance
    Estimation methodCockcroft-Gault formula

    Initial Deferasirox Therapy

    Initial Deferasirox Therapy

    Initiate only after documenting the applicable indication and laboratory evidence of chronic iron overload.

    Indication

    • ONE of: Chronic iron overload due to blood transfusions.
    • OR: Chronic iron overload due to a non-transfusion-dependent thalassemia syndrome.

    Laboratory evidence

    • Transfusional iron overload: Transfusion exposure is at least 100 mL/kg of packed red blood cells and serum ferritin is consistently above 1,000 mcg/L.≥100 mL/kg packed red blood cells; serum ferritin consistently >1,000 mcg/L

    Continuation and Dose Adjustment

    Continuation and Dose Adjustment

    Continue therapy with indication-specific laboratory monitoring and dose adjustment.

    Transfusional iron overload continuation: Adjust dose every 3–6 months based on serum ferritin trends, generally within 20–30 mg/kg/day; doses up to 40 mg/kg/day may be considered when serum ferritin remains above 2,500 mcg/L, and consider interruption when serum ferritin is below 500 mcg/L.Dose adjustment every 3–6 months; usual dose 20–30 mg/kg/day

    Doses above 40 mg/kg/day are not recommended.

    Non-transfusion-dependent thalassemia continuation: Monitor serum ferritin monthly and hepatic iron concentration every 6 months; interrupt below the specified ferritin or hepatic iron thresholds and resume when hepatic iron concentration exceeds 5 mg Fe/g dry weight.Interrupt LIC <3 mg Fe/g dry weight; resume LIC >5 mg Fe/g dry weight

    After 6 months, dose may be increased or reduced according to hepatic iron concentration.

    Concomitant Medication Considerations

    StepMedication-use requirementIf coadministration is necessary
    1Avoid concomitant bile acid sequestrants (e.g., cholestyramine, colesevelam, or colestipol) or potent UGT inducers (e.g., rifampin, phenytoin, phenobarbital, or ritonavir).Consider increasing the initial deferasirox dose by 50% and monitor serum ferritin and clinical response.
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyEXJADE (Deferasirox) Prior Authorization
    Policy CodePolicy N/A
    Change TypeArchivedno material clinical or coverage changes
    Effective DateJan 28, 2014
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionPrescribers must enroll patients in EPASS Complete Care before obtaining deferasirox.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Dose ParametersProvider Requirements and Safety ActionsTherapy BackgroundDefinitionsInitial Deferasirox TherapyContinuation and Dose AdjustmentConcomitant Medication Considerations
    LIC threshold
    Qualifying LICAt least 5 mg Fe/g liver dry weight
    Applies toNon-transfusion-dependent thalassemia syndromes
    Required withSerum ferritin greater than 300 mcg/L
    Ferritin threshold
    Qualifying ferritinGreater than 300 mcg/L
    Applies toNon-transfusion-dependent thalassemia syndromes
    Required withHepatic iron concentration at least 5 mg Fe/g liver dry weight
    Ferritin dose escalation
    Escalation thresholdSerum ferritin persistently greater than 2,500 mcg/L
    Potential doseUp to 40 mg/kg/day may be considered
    Dose limitDoses above 40 mg/kg/day are not recommended
    Ferritin interruption
    Interruption thresholdConsider interrupting therapy when serum ferritin is below 500 mcg/L
    Applies toTransfusional iron overload
    Reason notedRisk of toxicity may be increased
    Ferritin interruption
    Interruption thresholdSerum ferritin below 300 mcg/L
    Applies toNon-transfusion-dependent thalassemia syndromes
    Follow-upInterrupt therapy and obtain hepatic iron concentration
    LIC interruption
    Interruption thresholdHepatic iron concentration below 3 mg Fe/g dry weight
    Applies toNon-transfusion-dependent thalassemia syndromes
    Monitoring intervalMonitor hepatic iron concentration every 6 months
    LIC dose adjustment
    Dose escalationAfter 6 months, consider 20 mg/kg/day when hepatic iron concentration is greater than 7 mg Fe/g dry weight
    Dose reduction rangeReduce dose to 10 mg/kg or less when hepatic iron concentration is 3–7 mg Fe/g dry weight
    Maximum for this indicationDoses above 20 mg/kg/day are not recommended
    Renal contraindication
    Creatinine clearance criterionUse is contraindicated when CrCl is below 40 mL/minute
    Serum creatinine criterionUse is contraindicated when serum creatinine is greater than 2 times the age-appropriate ULN
    Action during treatmentDiscontinue treatment when either threshold is met
    Platelet contraindication
    Platelet thresholdPlatelet count below 50,000/mm3
    Treatment actionUse is contraindicated
    Toxicity managementInterrupt treatment for bone marrow suppression and determine the cause of cytopenia
    Documentation Required

    Document Initiation Evidence

    Before initiating therapy, document transfusion exposure and laboratory evidence of chronic iron overload appropriate to the indication.

    • Transfusional iron overload: transfusion of at least 100 mL/kg of packed red blood cells, such as at least 20 units for a 40-kg patient, and serum ferritin consistently greater than 1,000 mcg/L.
    • Non-transfusion-dependent thalassemia: hepatic iron concentration at least 5 mg Fe/g dry weight and serum ferritin greater than 300 mcg/L.
    Denial Risk

    Renal Function Monitoring

    Obtain renal function at baseline and monitor throughout treatment. Estimate creatinine clearance using the Cockcroft-Gault formula.

    • Determine serum creatinine and creatinine clearance twice at baseline and monthly thereafter.
    • For patients with renal impairment or risk of acute renal failure, monitor serum creatinine weekly for the first 4 weeks, then monthly.
    • At initiation, reduce the initial dose by 50% when creatinine clearance is 40–60 mL/minute; do not use when creatinine clearance is below 40 mL/minute or serum creatinine is greater than 2 times the age-appropriate ULN.

    Unsupported block type: denial_risk},{

    Transfusional iron overload
    TermTransfusional iron overload
    DefinitionIron overload caused by chronic red-blood-cell transfusion exposure
    Initiation evidenceAt least 100 mL/kg of packed red blood cells and serum ferritin consistently greater than 1,000 mcg/L
    Non-transfusion-dependent thalassemia
    TermNon-transfusion-dependent thalassemia syndrome
    DefinitionIron overload occurring in thalassemia syndromes without ongoing transfusion dependence
    Laboratory evidenceHepatic iron concentration at least 5 mg Fe/g dry weight and serum ferritin greater than 300 mcg/L
  1. Non-transfusion-dependent thalassemia: Hepatic iron concentration is at least 5 mg Fe/g dry weight and serum ferritin is above 300 mcg/L.LIC ≥5 mg Fe/g dry weight; serum ferritin >300 mcg/L